The Company is preparing to list its common shares on a national stock exchange in 2015.
2015 EXPECTED NEAR-TERM MILESTONES
"In a few short months from today, pending the acquisition of Cutanogen, the Company's Therapeutics division expects to have two ongoing mid-stage clinical studies in the areas of PD LID and severe burns, as well as a preclinical orphan ophthalmology program maturing towards the clinic. Management and the Board of Directors believes this scenario has the potential to be truly transformative for the Company and its shareholders. Moreover, during that same timeframe, we expect to make progress in executing on one of the strategic alternatives for the Diagnostics Division in order to generate further value for our shareholders," said Gerald. E. Commissiong, President and CEO of Amarantus. "While we have focused primarily on executing on our strategic initiatives to assemble and incubate undervalued, clinical assets towards feasibility milestones in each of these distinct divisions, going forward, we will be focused on executing on clinical, regulatory, commercial and corporate milestones to maximize their value."
Initiate a Phase 2b clinical study of eltoprazine in PD-LID in 2Q 2015;
Complete the acquisition of Cutanogen and then initiate a Phase 2 study mid-year 2015; and
Receive responses on our ODD applications for MANF in RAO from the FDA, and from the European Commissiong for MANF for the treatment of RP and RAO;
Continue to explore strategic options for our Diagnostics division, including a potential spin-off, to derive the full value of the Company's premier neuro-diagnostics business; and
Pursue an up-listing to a national stock exchange listing to position the Company for an appreciation in value.
"We have laid the groundwork for numerous opportunities to propel the Company forward with the goals of addressing unmet medical needs for patients that are so deserving of viable treatment options, and ultimately unlocking significant value for our loyal shareholders," concluded Mr. Commissiong. "Moving forward, our management team and board are committed to delivering on meaningful milestones on the clinical, regulatory and operational fronts by successfully executing on our business plan. Given this, we believe we have positioned Amarantus for an exciting 2015."
CONFERENCE CALL AND WEBCAST DETAILS
Amarantus Management will host a quarterly business update call on April 9, 2015. The business update may be accessed by telephone by dialing Toll-Free (US & Canada): 877-705-2969 or International: 201-689-8868; or by webcast on the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. Webcast participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.
2015 EXPECTED NEAR-TERM MILESTONES
"In a few short months from today, pending the acquisition of Cutanogen, the Company's Therapeutics division expects to have two ongoing mid-stage clinical studies in the areas of PD LID and severe burns, as well as a preclinical orphan ophthalmology program maturing towards the clinic. Management and the Board of Directors believes this scenario has the potential to be truly transformative for the Company and its shareholders. Moreover, during that same timeframe, we expect to make progress in executing on one of the strategic alternatives for the Diagnostics Division in order to generate further value for our shareholders," said Gerald. E. Commissiong, President and CEO of Amarantus. "While we have focused primarily on executing on our strategic initiatives to assemble and incubate undervalued, clinical assets towards feasibility milestones in each of these distinct divisions, going forward, we will be focused on executing on clinical, regulatory, commercial and corporate milestones to maximize their value."
Initiate a Phase 2b clinical study of eltoprazine in PD-LID in 2Q 2015;
Complete the acquisition of Cutanogen and then initiate a Phase 2 study mid-year 2015; and
Receive responses on our ODD applications for MANF in RAO from the FDA, and from the European Commissiong for MANF for the treatment of RP and RAO;
Continue to explore strategic options for our Diagnostics division, including a potential spin-off, to derive the full value of the Company's premier neuro-diagnostics business; and
Pursue an up-listing to a national stock exchange listing to position the Company for an appreciation in value.
"We have laid the groundwork for numerous opportunities to propel the Company forward with the goals of addressing unmet medical needs for patients that are so deserving of viable treatment options, and ultimately unlocking significant value for our loyal shareholders," concluded Mr. Commissiong. "Moving forward, our management team and board are committed to delivering on meaningful milestones on the clinical, regulatory and operational fronts by successfully executing on our business plan. Given this, we believe we have positioned Amarantus for an exciting 2015."
CONFERENCE CALL AND WEBCAST DETAILS
Amarantus Management will host a quarterly business update call on April 9, 2015. The business update may be accessed by telephone by dialing Toll-Free (US & Canada): 877-705-2969 or International: 201-689-8868; or by webcast on the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. Webcast participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.
